{"id":"interferon-gamma-1-b","safety":{"commonSideEffects":[{"rate":"26","effect":"Fever"},{"rate":"16","effect":"Headache"},{"rate":"14","effect":"Fatigue"},{"rate":"13","effect":"Myalgia"},{"rate":"8","effect":"Nausea"},{"rate":"7","effect":"Diarrhea"},{"rate":"14","effect":"Injection site erythema"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Interferon gamma (IFN-γ) is a Type II interferon produced by T cells and natural killer cells that acts as a key immunomodulatory cytokine. It binds to interferon gamma receptors on immune cells and tissue macrophages, enhancing their microbicidal and tumoricidal activity, increasing antigen presentation, and promoting Th1-mediated immune responses. The recombinant 1-b formulation is used to augment immune function in immunocompromised states or chronic granulomatous disease.","oneSentence":"Interferon Gamma 1-b is a recombinant cytokine that activates macrophages and enhances immune cell function to boost the body's antimicrobial and antitumor responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:16:36.055Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic granulomatous disease"},{"name":"Severe malignant osteopetrosis"},{"name":"Atypical mycobacterial infections in immunocompromised patients"}]},"trialDetails":[{"nctId":"NCT01212003","phase":"","title":"Training Protocol on the Natural History of Tuberculosis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-06-30","conditions":"Mycobacterium Infections, Tuberculosis, Multidrug-Resistant, Latent Tuberculosis","enrollment":150},{"nctId":"NCT06568484","phase":"PHASE2, PHASE3","title":"Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB","status":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-07","conditions":"Tuberculosis, Latent","enrollment":2530},{"nctId":"NCT05463133","phase":"PHASE1, PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-07-08","conditions":"Chronic Granulomatous Disease","enrollment":50},{"nctId":"NCT04926922","phase":"","title":"PREVAIL VIIIa: Evaluation of Latent Tuberculosis Infection Screening Methods in People Living With Retroviral Infection in Liberia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-07-27","conditions":"Tuberculosis, HIV","enrollment":200},{"nctId":"NCT00814827","phase":"","title":"Mycobacterial and Opportunistic Infections in HIV-Negative Thai and Taiwanese Patients Associated With Autoantibodies to Interferon-gamma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-01-07","conditions":"Nontuberculous Mycobacteria, Mycobacterium Tuberculosis, Opportunistic Infections","enrollment":224},{"nctId":"NCT05947890","phase":"PHASE2","title":"Evaluating the Safety and Immunogenicity of MTBVAC","status":"RECRUITING","sponsor":"HIV Vaccine Trials Network","startDate":"2024-01-30","conditions":"HIV I Infection, Tuberculosis","enrollment":276},{"nctId":"NCT04705818","phase":"PHASE2","title":"Combining Epigenetic And Immune Therapy to Beat Cancer.","status":"COMPLETED","sponsor":"Institut Bergonié","startDate":"2021-07-23","conditions":"Advanced Solid Tumor, Advanced Colorectal Carcinoma, Advanced Soft-tissue Sarcoma","enrollment":164},{"nctId":"NCT04328714","phase":"PHASE1","title":"Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease","status":"TERMINATED","sponsor":"Edwin Horwitz","startDate":"2021-12-02","conditions":"Acute Leukemia, Myelodysplastic Syndromes","enrollment":4},{"nctId":"NCT06052839","phase":"PHASE2","title":"Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC","status":"RECRUITING","sponsor":"Dan Zandberg","startDate":"2023-10-03","conditions":"Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)","enrollment":15},{"nctId":"NCT07244419","phase":"EARLY_PHASE1","title":"Prevention of Graft Rejection in Hematopoietic Stem Cell Transplant (HSCT) Recipients","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2026-01-07","conditions":"Hematopoietic Stem Cell Transplantation, Graft Failure","enrollment":20},{"nctId":"NCT06694740","phase":"PHASE2, PHASE3","title":"Effect of Interferon Gamma as a Treatment for Post-aggressive Immunosuppression in Intensive Care Units, a Randomized Bayesian Double-blind Controlled Trial Versus Placebo","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-01-12","conditions":"Post-aggressive Immunosuppression, Adult Patients Admitted to Intensive Care With Initial Severity (SOFA of the First 24 Hours Post-admission ≥ 6, Adult Under Mechanical Ventilation, and Presenting an mHLA-DR Less Than 8,000AB/C","enrollment":170},{"nctId":"NCT06430788","phase":"PHASE2","title":"A Study of Emapalumab for Pediatric Aplastic Anemia","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-05-21","conditions":"Aplastic Anemia, Cytopenia, Hypocellular Marrow","enrollment":35},{"nctId":"NCT05843786","phase":"PHASE3","title":"Human Recombinant Interferon Gamma in the Treatment of Ventilator-acquired Pneumonia in ICU Patients","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2023-06-30","conditions":"Pneumonia, Ventilator-Associated","enrollment":132},{"nctId":"NCT06774235","phase":"PHASE3","title":"Prevention of Secondary Infections by Interferon Gamma in ICU-acquired Sustained Immune-suppression","status":"RECRUITING","sponsor":"University Hospital, Limoges","startDate":"2025-07-09","conditions":"Sustained Immunosuppression","enrollment":326},{"nctId":"NCT06694701","phase":"PHASE2","title":"Emapalumab Treatment For Anticipated Clinical Benefit In Sepsis Driven By The Interferon-Gamma Endotype (The EMBRACE Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hellenic Institute for the Study of Sepsis","startDate":"2025-03-22","conditions":"Sepsis","enrollment":75},{"nctId":"NCT06550141","phase":"PHASE2","title":"Emapalumab Prevention of CAR-T Cell Associated Toxicities","status":"RECRUITING","sponsor":"Marcela V. Maus, M.D.,Ph.D.","startDate":"2024-09-18","conditions":"Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma","enrollment":28},{"nctId":"NCT05400122","phase":"PHASE1","title":"Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer","status":"SUSPENDED","sponsor":"David Wald","startDate":"2022-09-09","conditions":"Colorectal Cancer, Hematologic Malignancy, Rectum Cancer","enrollment":12},{"nctId":"NCT06545812","phase":"NA","title":"Immune Response During the Conservative and Minimal Invasive Treatment of Pain Caused by Lumbar Disc Herniation","status":"RECRUITING","sponsor":"Josip Juraj Strossmayer University of Osijek","startDate":"2024-09-02","conditions":"Intervertebral Disc Herniation, Back Pain, Analgesic Nephropathy","enrollment":128},{"nctId":"NCT06909110","phase":"PHASE1, PHASE2","title":"Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity","status":"RECRUITING","sponsor":"Jessie L. Alexander","startDate":"2025-04-30","conditions":"Adenovirus, Cytomegalovirus Infections, Epstein-Barr Virus Infections","enrollment":25},{"nctId":"NCT06602869","phase":"","title":"Cellular Markers in Treated or Untreated Non-tuberculous Mycobacterial Respiratory Infection in Patients With Cystic Fibrosis","status":"RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2024-09-17","conditions":"Non-Tuberculous Mycobacterial Pneumonia","enrollment":76},{"nctId":"NCT02143518","phase":"PHASE1","title":"Safety and Immunogenicity Study of Na-GST-1 With or Without CpG","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2014-10","conditions":"Hookworm Infection, Hookworm Disease","enrollment":24},{"nctId":"NCT06047132","phase":"","title":"PREDICTIVE ABILITY OF A PANEL OF BIOMARKERS IN SALIVA IN HEALTHY AND PERIODONTALLY AFFECTED SUBJECTS","status":"COMPLETED","sponsor":"Universidad Complutense de Madrid","startDate":"2023-10-23","conditions":"Periodontitis, Saliva, Biomarkers","enrollment":100},{"nctId":"NCT06027879","phase":"PHASE1, PHASE2","title":"Anti-viral T-cell Therapy by Gamma Capture","status":"ENROLLING_BY_INVITATION","sponsor":"Paul Szabolcs","startDate":"2024-01-08","conditions":"Adenovirus, Cytomegalovirus Infections, Epstein-Barr Virus Infections","enrollment":25},{"nctId":"NCT05035862","phase":"PHASE1","title":"Mechanisms of Interferon Gamma-primed Mesenchymal Stromal Cells (MSCs) for Moderate-to-severe Persistent Asthma","status":"TERMINATED","sponsor":"Emory University","startDate":"2022-03-16","conditions":"Asthma","enrollment":1},{"nctId":"NCT06996119","phase":"PHASE1","title":"Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-05-25","conditions":"Acute Myeloid Leukemia, Graft Versus Host Disease, Myelodysplastic Syndrome","enrollment":15},{"nctId":"NCT06221488","phase":"","title":"Testing Health Workers At Risk to Advance Our Understanding of TB Infection","status":"RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2024-01-15","conditions":"Tuberculosis, Tuberculosis Infection","enrollment":300},{"nctId":"NCT02380443","phase":"PHASE2","title":"AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Mirror Biologics, Inc.","startDate":"2016-09","conditions":"Colorectal Cancer Metastatic","enrollment":13},{"nctId":"NCT04722029","phase":"PHASE1, PHASE2","title":"Pilot Study of Haploidentical Donor Adenovirus Specific T-lymphocytes to Treat Refractory Adenovirus Infections","status":"RECRUITING","sponsor":"Nationwide Children's Hospital","startDate":"2021-10-01","conditions":"Adenovirus Infection","enrollment":12},{"nctId":"NCT04489732","phase":"PHASE1","title":"MSC in Patients With Xerostomia Post XRT in Head and Neck Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2022-02-18","conditions":"Xerostomia Following Radiotherapy","enrollment":6},{"nctId":"NCT06352970","phase":"","title":"Effects of Tuberculosis Infection on Development and Function of the Placenta","status":"RECRUITING","sponsor":"Lund University","startDate":"2024-10-01","conditions":"Pregnancy Related, Tuberculosis Infection, Placenta Diseases","enrollment":500},{"nctId":"NCT03747484","phase":"PHASE1, PHASE2","title":"Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2019-07-03","conditions":"Other Skin","enrollment":7},{"nctId":"NCT05653193","phase":"PHASE2","title":"Interferon-gamma as Adjunctive Therapy in Chronic Pulmonary Aspergillosis: a Randomised Feasibility Study","status":"RECRUITING","sponsor":"Manchester University NHS Foundation Trust","startDate":"2024-05-17","conditions":"Chronic Pulmonary Aspergillosis, Aspergillosis","enrollment":50},{"nctId":"NCT06852846","phase":"NA","title":"Clinical Usefulness of a Multi-analyte Immunoassay for Distinguishing Bacterial and Viral Infections in Children","status":"ACTIVE_NOT_RECRUITING","sponsor":"Meyer Children's Hospital IRCCS","startDate":"2024-09-23","conditions":"Febrile Illness","enrollment":100},{"nctId":"NCT05100043","phase":"","title":"Interleukin 4 and Interferon Gamma Predictors of Human Papillomavirus Immunotherapy in Warts","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2020-01-03","conditions":"Warts Hand, Wart, Genital","enrollment":80},{"nctId":"NCT05005637","phase":"PHASE2","title":"The Effectivity of Anti Tuberculosis Therapy in Idiopathic Uveitis with Positive IGRA","status":"COMPLETED","sponsor":"Fakultas Kedokteran Universitas Indonesia","startDate":"2021-08-27","conditions":"Tuberculous Uveitis","enrollment":78},{"nctId":"NCT06794502","phase":"EARLY_PHASE1","title":"Butterfly Pea Flower (Clitoria Ternatea) for Adjuvant TB Treatment","status":"COMPLETED","sponsor":"Universitas Muhammadiyah Semarang","startDate":"2024-03-14","conditions":"Tuberculosis (TB), Tuberculosis Treatment Effectiveness","enrollment":28},{"nctId":"NCT02593773","phase":"PHASE3","title":"Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-12-25","conditions":"Friedreich's Ataxia","enrollment":86},{"nctId":"NCT02415127","phase":"PHASE3","title":"Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-06","conditions":"Friedreich's Ataxia","enrollment":92},{"nctId":"NCT04979052","phase":"PHASE2","title":"Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia","status":"RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2022-03-31","conditions":"Candidemia","enrollment":200},{"nctId":"NCT05190146","phase":"","title":"Epidemiologic Study to Assess the IGRA Positivity in Populations With a High TB Burden","status":"COMPLETED","sponsor":"Gates Medical Research Institute","startDate":"2021-12-20","conditions":"Tuberculosis, Pulmonary","enrollment":7203},{"nctId":"NCT02922998","phase":"","title":"CD64 and Antibiotics in Human Sepsis","status":"COMPLETED","sponsor":"University of Ulm","startDate":"2016-09","conditions":"Antibiotic Resistant Infection, Critical Illness, SIRS","enrollment":64},{"nctId":"NCT06700876","phase":"","title":"Evaluation of IGRA, Symptoms and Chest Radiograph for Subclinical TB Detection in ESRD and KT","status":"RECRUITING","sponsor":"Mahidol University","startDate":"2024-08-06","conditions":"Tuberculosis (TB), End-Stage Kidney Disease","enrollment":160},{"nctId":"NCT05235711","phase":"","title":"The Role of Interferon-gamma in Immune Responses to Invasive Candidiasis","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2022-02-10","conditions":"Fungal Infection, Candidiasis","enrollment":87},{"nctId":"NCT06629194","phase":"","title":"Validation of Scoring Systems for Differentiating Intestinal Tuberculosis from Crohn's Disease","status":"RECRUITING","sponsor":"Mahidol University","startDate":"2024-06-09","conditions":"Crohn Disease, Intestinal Tuberculosis, Differential Diagnosis","enrollment":84},{"nctId":"NCT06341543","phase":"NA","title":"Quantiferon CMV to Identify Treatment Need for Asymptomatic CMV Infection After Solid Organ Transplant (QUANTIFOT)","status":"RECRUITING","sponsor":"University Hospital, Grenoble","startDate":"2024-09-24","conditions":"Cytomegalovirus Infections, Heart Transplantation, Kidney Transplantation","enrollment":288},{"nctId":"NCT05724212","phase":"","title":"Evaluation of a CD4/CD8+ Interferon Gamma Release Assay for Monitoring Anti-Tuberculosis Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Paola Mantegani","startDate":"2017-01-27","conditions":"Tuberculosis","enrollment":220},{"nctId":"NCT06344052","phase":"PHASE2","title":"To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma","status":"RECRUITING","sponsor":"Stamford Pharmaceuticals, Inc.","startDate":"2024-04-09","conditions":"Basal Cell Carcinoma","enrollment":80},{"nctId":"NCT06047210","phase":"","title":"Evaluation of IFNγ and Inflammatory Mediators in Patients With Hemophagocytic Lymphohistiocytosis","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2016-12-14","conditions":"Hemophagocytic Lymphohistiocytoses","enrollment":14},{"nctId":"NCT03259230","phase":"","title":"Evaluation of IFNγ and Inflammatory Mediators in Patients With Malignancy-Associated Hemophagocytic Lymphohistiocytosis","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2016-10-13","conditions":"Hemophagocytic Lymphohistiocytosis","enrollment":40},{"nctId":"NCT05054114","phase":"NA","title":"Study of the Use of Nasal IFN-γ in Patients for the Prevention of Acute Respiratory Viral Infections, Icluding COVID-19","status":"COMPLETED","sponsor":"SPP Pharmaclon Ltd.","startDate":"2020-12-21","conditions":"COVID-19 Respiratory Infection, Acute Respiratory Disease","enrollment":630},{"nctId":"NCT03572842","phase":"NA","title":"Functional Non Specific Immunity Monitoring After Kidney Transplantation Using an Interferon Gamma Test","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2019-01-24","conditions":"Kidney Transplantation","enrollment":134},{"nctId":"NCT03984890","phase":"PHASE2, PHASE3","title":"Vitamin D3 For CGD Patients With BCGosis/Itis","status":"COMPLETED","sponsor":"Children's Hospital of Fudan University","startDate":"2019-08-01","conditions":"Vitamin D3, Chronic-granulomatous Disease, BCG","enrollment":50},{"nctId":"NCT06371482","phase":"PHASE2","title":"Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2023-06-01","conditions":"SCLC, Limited Stage","enrollment":58},{"nctId":"NCT06222801","phase":"","title":"The 1st Tumor CytokinoTherapy Database (TCTD-1)","status":"RECRUITING","sponsor":"OncoCareClinic 308 Ltd","startDate":"2022-09-19","conditions":"Oncology","enrollment":5000},{"nctId":"NCT06408129","phase":"","title":"COMPArison of Screening Strategies for Active TuBerculosis (COMPASS-TB)","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2017-01-31","conditions":"Active Tuberculosis, Latent Tuberculosis","enrollment":580},{"nctId":"NCT06402734","phase":"","title":"Effects of Gluten-Free Diet on Nutritional Status in Celiac Patients","status":"COMPLETED","sponsor":"Hacettepe University","startDate":"2018-10-15","conditions":"Celiac Disease","enrollment":52},{"nctId":"NCT04364178","phase":"PHASE1, PHASE2","title":"Viral Specific T-Lymphocytes to Treat Adenovirus or CMV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jessie L. Alexander","startDate":"2020-08-12","conditions":"Adenovirus, Cytomegalovirus Infections","enrollment":25},{"nctId":"NCT03312751","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Emapalumab in Primary Haemophagocytic Lymphohistiocytosis","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2019-02-06","conditions":"Primary Hemophagocytic Lymphohistiocytosis","enrollment":35},{"nctId":"NCT04088019","phase":"","title":"Proportion of Clinical Improvement & Type 1 Interferon (IFN) Score Changes in Idiopathic Uveitis Patients With Interferon Gamma Release Assay (IGRA) Positive","status":"UNKNOWN","sponsor":"Fakultas Kedokteran Universitas Indonesia","startDate":"2019-10-30","conditions":"Tuberculosis; Uveitis (Manifestation), Anti-Tuberculous Drug Reaction, Tuberculous Uveitis","enrollment":50},{"nctId":"NCT01468337","phase":"PHASE1, PHASE2","title":"Topical Interferon Gamma-1b for Central Serous Chorioretinopathy","status":"COMPLETED","sponsor":"National Eye Institute (NEI)","startDate":"2011-10","conditions":"Retinal Disease, Macular Disease","enrollment":5},{"nctId":"NCT05065905","phase":"PHASE1, PHASE2","title":"Study of Interferon-Gamma in the Complex Treatment of Patients Infected With HIV and Tuberculosis","status":"COMPLETED","sponsor":"SPP Pharmaclon Ltd.","startDate":"2006-01-19","conditions":"HIV Coinfection, Aids/Hiv Problem, Tuberculosis, Pulmonary","enrollment":78},{"nctId":"NCT04731298","phase":"PHASE2","title":"Study to Investigate the Pharmacokinetics, Pharmacodynamics and Assess the Efficacy and Safety to Support Dose Selection of Emapalumab in Pre-empting Graft Failure in Patients at High Risk After HSCT.","status":"TERMINATED","sponsor":"Swedish Orphan Biovitrum","startDate":"2021-05-25","conditions":"Graft Failure","enrollment":2},{"nctId":"NCT04369794","phase":"PHASE4","title":"COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement","status":"COMPLETED","sponsor":"University of Campinas, Brazil","startDate":"2020-10-01","conditions":"COVID-19, Therapeutic Vaccine, BCG","enrollment":400},{"nctId":"NCT04781257","phase":"","title":"Early Risk Assessment in Household Contacts (≥10 Years) of TB Patients by New Diagnostic Tests in 3 African Countries","status":"UNKNOWN","sponsor":"Michael Hoelscher","startDate":"2021-03-01","conditions":"Tuberculosis","enrollment":2100},{"nctId":"NCT04523246","phase":"EARLY_PHASE1","title":"Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents","status":"COMPLETED","sponsor":"University of Oklahoma","startDate":"2020-09-01","conditions":"Herpes Zoster, Allergy and Immunology, Corona Virus Infection","enrollment":217},{"nctId":"NCT06135818","phase":"NA","title":"Same Day Diagnosis of Extrapulmonary TB (TB Serositis and TB Meningitis).","status":"RECRUITING","sponsor":"University of Cape Town","startDate":"2021-03-16","conditions":"Tuberculosis, Extrapulmonary","enrollment":2160},{"nctId":"NCT06118619","phase":"","title":"A Multicenter Clinical Trial of Ingaron in Pulmonary Tuberculosis","status":"UNKNOWN","sponsor":"SPP Pharmaclon Ltd.","startDate":"2022-06-01","conditions":"Respiratory Tuberculosis","enrollment":350},{"nctId":"NCT03063632","phase":"PHASE2","title":"Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-12-14","conditions":"Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma, Metastatic Synovial Sarcoma","enrollment":28},{"nctId":"NCT05541952","phase":"PHASE4","title":"BCG Re-vaccination for Primary Tuberculosis Prophylaxis in the Prison Population","status":"WITHDRAWN","sponsor":"Federal University of Mato Grosso","startDate":"2020-08-17","conditions":"Latent Tuberculosis","enrollment":""},{"nctId":"NCT05354583","phase":"","title":"Treatment Outcome Between Mycobacterium Abscessus Infection in Chronic Lung Disease and Acquired Interferon-gamma Autoantibody Syndrome","status":"COMPLETED","sponsor":"King Chulalongkorn Memorial Hospital","startDate":"2022-06-15","conditions":"Mycobacterium Abscessus Infection, Adult-Onset Immunodeficiency With Acquired Anti-Interferon-Gamma Autoantibodies, Nontuberculous Mycobacterial Pulmonary Infection","enrollment":36},{"nctId":"NCT03985423","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients With HLH","status":"TERMINATED","sponsor":"Swedish Orphan Biovitrum","startDate":"2020-06-02","conditions":"Hemophagocytic Lymphohistiocytoses","enrollment":7},{"nctId":"NCT05783544","phase":"NA","title":"Impact of A. Lumbricoides on Pulmonary Aspergillosis Development","status":"UNKNOWN","sponsor":"Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan","startDate":"2015-05-01","conditions":"COPD Exacerbation Acute, Ascaris Lumbricoides Infection, Chronic Pulmonary Aspergillosis","enrollment":200},{"nctId":"NCT05367882","phase":"","title":"Effect of Interleukin 6 Receptor Antagonists in SARS-CoV-2 Patients","status":"COMPLETED","sponsor":"Assiut University","startDate":"2022-02-01","conditions":"Corona Virus Infection","enrollment":96},{"nctId":"NCT02512939","phase":"NA","title":"Predictive Values of Next Generation Interferon Gamma Release Assays for Latent Tuberculosis Infection","status":"COMPLETED","sponsor":"University College, London","startDate":"2015-07","conditions":"Tuberculosis","enrollment":675},{"nctId":"NCT03112590","phase":"PHASE1, PHASE2","title":"Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2017-06-23","conditions":"Breast Cancer, Breast Cancer, Male, Breast Cancer Female","enrollment":51},{"nctId":"NCT04916847","phase":"","title":"Comparative Analysis of Anti-COVID-19 (Severe Acute Respiratory Syndrome) Humoral and Memory T Cell Responses in Children With Various Degrees of Immunosuppression:","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-06-07","conditions":"Immune Response","enrollment":205},{"nctId":"NCT05089565","phase":"","title":"Immune Response to SARS-CoV-2/COVID-19 Vaccination in Sarcoidosis","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2021-12-01","conditions":"Sarcoidosis, SARS-CoV2 Infection, Vaccine Response Impaired","enrollment":101},{"nctId":"NCT05699577","phase":"","title":"Prognostic Value of Some Biochemical Markers in Breast Cancer","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2023-02","conditions":"Breast Cancer Female","enrollment":90},{"nctId":"NCT04918940","phase":"NA","title":"Efficacy of COVID-19 Vaccination in Patientstreated With Anti-CD20 for Follicular Lymphoma or Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Centre Henri Becquerel","startDate":"2021-05-21","conditions":"Follicular Lymphoma, Mantle Cell Lymphoma","enrollment":20},{"nctId":"NCT04494061","phase":"","title":"A Clinical Study to Investigate Interferon Gamma (IFNɣ) Signature in Patients Post HSCT and in Patients With Impaired HSC Proliferation Pre-transplant","status":"TERMINATED","sponsor":"Swedish Orphan Biovitrum","startDate":"2020-11-16","conditions":"Graft Failure","enrollment":101},{"nctId":"NCT05491304","phase":"PHASE4","title":"Cytokine Guided Risk Stratification and Treatment in Pediatric Hemophagocytic Lymphohistiocytosis","status":"UNKNOWN","sponsor":"The Children's Hospital of Zhejiang University School of Medicine","startDate":"2022-09-01","conditions":"Hemophagocytic Lymphohistiocytoses, Cytokine Storm","enrollment":400},{"nctId":"NCT04898140","phase":"","title":"The Evaluation of Cellular and Humoral Immunity to COVID-19 in Moscow Residents","status":"COMPLETED","sponsor":"Moscow Department of Health","startDate":"2020-10-20","conditions":"Covid19, Respiratory Viral Infection","enrollment":5340},{"nctId":"NCT03767946","phase":"","title":"Epidemiological Study In Tuberculosis-Endemic Urban Area in Senegal","status":"COMPLETED","sponsor":"Biomedical Research Center EPLS","startDate":"2018-07-27","conditions":"Tuberculosis","enrollment":500},{"nctId":"NCT05338736","phase":"","title":"Humoral and Cellular Immunity in First-cycle SARS-CoV-2 Vaccinated COVID-19 Patients","status":"COMPLETED","sponsor":"University Magna Graecia","startDate":"2022-04-01","conditions":"SARS CoV 2 Infection, COVID-19","enrollment":45},{"nctId":"NCT02069899","phase":"PHASE2, PHASE3","title":"A Study for Long-term Follow-up of Hemophagocytic Lymphohistiocytosis (HLH) Participants Who Received Treatment With Emapalumab (NI-0501), an Anti-interferon Gamma Monoclonal Antibody","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2014-08-04","conditions":"Hemophagocytic Lymphohistiocytosis","enrollment":58},{"nctId":"NCT01037907","phase":"PHASE2","title":"A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)","status":"TERMINATED","sponsor":"Boston Scientific Corporation","startDate":"2009-11","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":173},{"nctId":"NCT05359315","phase":"","title":"Study on the Use of Interferon Gamma (Ingaron) Injections in Patients With Drug-resistant Pulmonary Tuberculosis","status":"UNKNOWN","sponsor":"SPP Pharmaclon Ltd.","startDate":"2022-04-15","conditions":"Pulmonary Tuberculosis","enrollment":84},{"nctId":"NCT05395702","phase":"NA","title":"Study of Ingaron's Effect on Efficacy and Resistance to Antibiotics in Community-acquired Pneumonia","status":"COMPLETED","sponsor":"SPP Pharmaclon Ltd.","startDate":"2017-05-12","conditions":"Community-acquired Pneumonia","enrollment":114},{"nctId":"NCT05386459","phase":"","title":"Study of the Use of the Drug Ingaron in Patients With COVID-19","status":"COMPLETED","sponsor":"SPP Pharmaclon Ltd.","startDate":"2020-04-21","conditions":"COVID-19 Respiratory Infection, Viral Pneumonia","enrollment":36},{"nctId":"NCT05386446","phase":"","title":"Study of the Use of the Ingaron in Volunteers for the Prevention of COVID-19","status":"COMPLETED","sponsor":"SPP Pharmaclon Ltd.","startDate":"2020-04-23","conditions":"COVID-19 Respiratory Infection","enrollment":100},{"nctId":"NCT05378646","phase":"PHASE3","title":"Efficiency and Safety of the Drug Ingaron (Interferon-gamma Human Recombinant) in the Treatment of Chronic Prostatitis","status":"COMPLETED","sponsor":"SPP Pharmaclon Ltd.","startDate":"2009-01-29","conditions":"Chronic Prostatitis","enrollment":30},{"nctId":"NCT03311854","phase":"PHASE2","title":"A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2018-02-20","conditions":"Macrophage Activation Syndrome, Lymphohistiocytosis, Hemophagocytic, Arthritis, Juvenile","enrollment":14},{"nctId":"NCT04881396","phase":"","title":"Response of Haemodialysis Patients to BNT162b2 mRNA Cov-19 Vaccine","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2021-05-10","conditions":"COVID-19 Vaccines, Hemodialysis Complication","enrollment":99},{"nctId":"NCT03161756","phase":"PHASE1, PHASE2","title":"Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma","status":"UNKNOWN","sponsor":"Melanoma and Skin Cancer Trials Limited","startDate":"2017-12-07","conditions":"Melanoma Stage Iv, Melanoma Stage Iii, Melanoma","enrollment":72},{"nctId":"NCT05311423","phase":"","title":"The Prevalence and Reproductive Outcome of Infertile Women With Genital Tuberculosis","status":"UNKNOWN","sponsor":"Huashan Hospital","startDate":"2021-12-01","conditions":"Infertility, Female, Genital Tuberculoses, Female","enrollment":3000},{"nctId":"NCT04324021","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.","status":"TERMINATED","sponsor":"Swedish Orphan Biovitrum","startDate":"2020-04-02","conditions":"SARS-CoV-2","enrollment":16},{"nctId":"NCT04793568","phase":"PHASE2","title":"Human Recombinant Interferon Gamma-1b for the Prevention of Hospital-acquired Pneumonia in Critically Ill Patients: a Double-blind, International, Phase 2, Randomized, Placebo-controlled Trial - the PREV-HAP Study","status":"UNKNOWN","sponsor":"Nantes University Hospital","startDate":"2021-03-29","conditions":"Critically Ill Patients","enrollment":109},{"nctId":"NCT00604617","phase":"","title":"Interferon-Gamma Release Assays in Tuberculosis (TB) - HIV Co-infected Children","status":"COMPLETED","sponsor":"Case Western Reserve University","startDate":"2009-01-26","conditions":"Tuberculosis, HIV","enrollment":564},{"nctId":"NCT05057936","phase":"","title":"Antibody After COVID-19 Vaccination","status":"COMPLETED","sponsor":"Bangkok Metropolitan Administration Medical College and Vajira Hospital","startDate":"2021-06-01","conditions":"Covid19, Breakthrough Infection, CKD","enrollment":140},{"nctId":"NCT05165719","phase":"","title":"Validation of 'Corona-T-test' for Assessment of SARS-COV-2-specific T-cell Response After COVID-19 or Vaccination","status":"COMPLETED","sponsor":"National Research Center for Hematology, Russia","startDate":"2021-07-07","conditions":"SARS-CoV-2 Infection, SARS-CoV-2 Vaccination","enrollment":220}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Interferon Gamma 1-b","genericName":"Interferon Gamma 1-b","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Interferon Gamma 1-b is a recombinant cytokine that activates macrophages and enhances immune cell function to boost the body's antimicrobial and antitumor responses. Used for Chronic granulomatous disease, Severe malignant osteopetrosis, Atypical mycobacterial infections in immunocompromised patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}